Omnicell, Inc. (NASDAQ:OMCL – Get Rating) – KeyCorp issued their Q1 2023 earnings estimates for shares of Omnicell in a report issued on Tuesday, September 20th. KeyCorp analyst S. Schoenhaus anticipates that the company will earn $0.64 per share for the quarter. KeyCorp has a “Overweight” rating and a $130.00 price objective on the stock. The consensus estimate for Omnicell’s current full-year earnings is $2.60 per share. KeyCorp also issued estimates for Omnicell’s Q2 2023 earnings at $0.69 EPS, Q3 2023 earnings at $0.86 EPS, Q4 2023 earnings at $0.98 EPS and FY2023 earnings at $3.16 EPS.
Omnicell (NASDAQ:OMCL – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.01). The firm had revenue of $331.39 million for the quarter, compared to analyst estimates of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.71 EPS.
Omnicell Trading Down 5.0 %
Shares of OMCL opened at $86.30 on Thursday. The stock’s fifty day simple moving average is $105.93 and its 200-day simple moving average is $114.36. The firm has a market capitalization of $3.82 billion, a PE ratio of 68.64, a price-to-earnings-growth ratio of 2.60 and a beta of 1.06. Omnicell has a 12-month low of $86.02 and a 12-month high of $187.29. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 0.52.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Raymond James & Associates grew its stake in shares of Omnicell by 8.9% during the 1st quarter. Raymond James & Associates now owns 128,877 shares of the company’s stock worth $16,688,000 after acquiring an additional 10,487 shares in the last quarter. Swiss National Bank lifted its position in Omnicell by 8.6% during the 1st quarter. Swiss National Bank now owns 103,900 shares of the company’s stock worth $13,454,000 after buying an additional 8,200 shares in the last quarter. Lindenwold Advisors acquired a new position in shares of Omnicell during the 4th quarter worth about $377,000. Capital Fund Management S.A. bought a new position in shares of Omnicell in the 1st quarter valued at about $1,392,000. Finally, Handelsbanken Fonder AB increased its position in shares of Omnicell by 27.9% in the first quarter. Handelsbanken Fonder AB now owns 9,623 shares of the company’s stock valued at $1,246,000 after acquiring an additional 2,100 shares during the last quarter.
Insider Transactions at Omnicell
In related news, CEO Randall A. Lipps sold 13,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $111.04, for a total value of $1,443,520.00. Following the completion of the transaction, the chief executive officer now directly owns 302,049 shares in the company, valued at approximately $33,539,520.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Omnicell news, CEO Randall A. Lipps sold 13,000 shares of Omnicell stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total value of $1,443,520.00. Following the transaction, the chief executive officer now owns 302,049 shares of the company’s stock, valued at $33,539,520.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Peter J. Kuipers sold 15,500 shares of the stock in a transaction on Friday, August 26th. The stock was sold at an average price of $108.29, for a total transaction of $1,678,495.00. Following the sale, the chief financial officer now directly owns 61,326 shares of the company’s stock, valued at approximately $6,640,992.54. The disclosure for this sale can be found here. Insiders have sold a total of 39,500 shares of company stock valued at $4,287,245 over the last 90 days. 2.76% of the stock is owned by company insiders.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.